{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T16:17:24Z","timestamp":1773418644496,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:00:00Z","timestamp":1761177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s10096-025-05320-4","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T03:28:39Z","timestamp":1761190119000},"page":"375-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting"],"prefix":"10.1007","volume":"45","author":[{"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Dobrzeniecka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Talarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Aniszewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,23]]},"reference":[{"issue":"6","key":"5320_CR1","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S2468-1253(19)30046-9","volume":"4","author":"G Indolfi","year":"2019","unstructured":"Indolfi G, Easterbrook P, Dusheiko G, El-Sayed MH, Jonas MM, Thorne C et al (2019) Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol 4(6):477\u2013487","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"5320_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100227","volume":"3","author":"F Malik","year":"2021","unstructured":"Malik F, Bailey H, Chan P, Collins IJ, Mozalevskis A, Thorne C et al (2021) Where are the children in National hepatitis C policies? A global review of National strategic plans and guidelines. JHEP Rep 3(2):100227","journal-title":"JHEP Rep"},{"issue":"2","key":"5320_CR3","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/hep.28995","volume":"66","author":"WF Balistreri","year":"2017","unstructured":"Balistreri WF, Murray KF, Rosenthal P, Bansal S, Lin CH, Kersey K et al (2017) The safety and effectiveness of ledipasvir-sofosbuvir in adolescents 12\u201317 years old with hepatitis C virus genotype 1 infection. Hepatology 66(2):371\u2013378","journal-title":"Hepatology"},{"issue":"6","key":"5320_CR4","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1002\/jpn3.12045","volume":"78","author":"MM Jonas","year":"2024","unstructured":"Jonas MM, Romero R, Rosenthal P, Lin CH, Verucchi G, Wen J et al (2024) Sofosbuvir-velpatasvir in children 3\u201317 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 78(6):1342\u20131354","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"6","key":"5320_CR5","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1002\/hep.30123","volume":"68","author":"KF Murray","year":"2018","unstructured":"Murray KF, Balistreri WF, Bansal S, Whitworth S, Evans HM, Gonzalez-Peralta RP et al (2018) Safety and efficacy of Ledipasvir-Sofosbuvir with or without ribavirin for chronic hepatitis C in children ages 6\u201311. Hepatology 68(6):2158\u20132166","journal-title":"Hepatology"},{"issue":"1","key":"5320_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1002\/hep.30821","volume":"71","author":"P Rosenthal","year":"2020","unstructured":"Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, Lin CH, Kelly DA, Nightingale S et al (2020) Sofosbuvir and ribavirin therapy for children aged 3 to <\u200912 years with hepatitis C virus genotype 2 or 3 infection. Hepatology 71(1):31\u201343","journal-title":"Hepatology"},{"issue":"2","key":"5320_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1002\/hep.30830","volume":"71","author":"KB Schwarz","year":"2020","unstructured":"Schwarz KB, Rosenthal P, Murray KF, Honegger JR, Hardikar W, Hague R et al (2020) Ledipasvir-Sofosbuvir for 12 weeks in children 3 to <\u20096 years old with chronic hepatitis C. Hepatology 71(2):422\u2013430","journal-title":"Hepatology"},{"issue":"2","key":"5320_CR8","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/hep.30840","volume":"71","author":"MM Jonas","year":"2020","unstructured":"Jonas MM, Squires RH, Rhee SM, Lin CW, Bessho K, Feiterna-Sperling C et al (2020) Pharmacokinetics, safety, and efficacy of Glecaprevir\/Pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study. Hepatology 71(2):456\u2013462","journal-title":"Hepatology"},{"issue":"3","key":"5320_CR9","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000031","volume":"7","author":"RP Gonzalez-Peralta","year":"2023","unstructured":"Gonzalez-Peralta RP, Wirth S, Squires RH, Mutschler F, Lang T, Pawlowska M et al (2023) Elbasvir\/grazoprevir in children aged 3\u201318 years with chronic HCV genotype 1 or 4 infection: a pharmacokinetic modeling study. Hepatol Commun 7(3):e0031","journal-title":"Hepatol Commun"},{"issue":"1","key":"5320_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31841","volume":"74","author":"MM Jonas","year":"2021","unstructured":"Jonas MM, Rhee S, Kelly DA, Del Valle-Segarra A, Feiterna-Sperling C, Gilmour S et al (2021) Pharmacokinetics, safety, and efficacy of Glecaprevir\/Pibrentasvir in children with chronic HCV: part 2 of the DORA study. Hepatology 74(1):19\u201327","journal-title":"Hepatology"},{"issue":"2","key":"5320_CR11","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1002\/hep.32393","volume":"76","author":"G Indolfi","year":"2022","unstructured":"Indolfi G, Kelly D, Nebbia G, Iorio R, Mania A, Giacomet V et al (2022) Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Hepatology 76(2):445\u2013455","journal-title":"Hepatology"},{"key":"5320_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jpn3.12160","author":"G Indolfi","year":"2024","unstructured":"Indolfi G, Gonzalez-Peralta RP, Jonas MM, Sayed MH, Fischler B, Sokal E (2024) ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource\u2010limited settings. J Pediatr Gastroenterol Nutr. https:\/\/doi.org\/10.1002\/jpn3.12160","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"5320_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15827","author":"G Indolfi","year":"2024","unstructured":"Indolfi G, Easterbrook P, Giometto S, Malik F, Chou R, Lucenteforte E (2024) Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis. Liver Int. https:\/\/doi.org\/10.1111\/liv.15827","journal-title":"Liver Int"},{"key":"5320_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10184176","author":"M Pokorska-\u015apiewak","year":"2021","unstructured":"Pokorska-\u015apiewak M, Dobrzeniecka A, Aniszewska M, Marczy\u0144ska M (2021) Real-life experience with Ledipasvir\/Sofosbuvir for the treatment of chronic hepatitis C virus infection with genotypes 1 and 4 in children aged 12 to 17 years-results of the POLAC project. J Clin Med. https:\/\/doi.org\/10.3390\/jcm10184176","journal-title":"J Clin Med"},{"issue":"4","key":"5320_CR15","doi-asserted-by":"publisher","first-page":"574","DOI":"10.3390\/idr14040061","volume":"14","author":"M Pokorska-\u015apiewak","year":"2022","unstructured":"Pokorska-\u015apiewak M, Dobrzeniecka A, Ogrodnik A (2022) Efficacy and safety of the treatment of chronic hepatitis c with Sofosbuvir\/Ledipasvir in children aged 5 to 10 years with comorbidities-a brief report. Infect Dis Rep 14(4):574\u2013578","journal-title":"Infect Dis Rep"},{"issue":"9","key":"5320_CR16","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/liv.15637","volume":"43","author":"M Pokorska-\u015apiewak","year":"2023","unstructured":"Pokorska-\u015apiewak M, Talarek E, Aniszewska M, Pluta M, Dobrzeniecka A, Marczy\u0144ska M et al (2023) Efficacy and safety of treatment with sofosbuvir\/velpatasvir in patients aged 6\u201318 years with chronic hepatitis C-results of the PANDAA-PED study. Liver Int 43(9):1871\u20131878","journal-title":"Liver Int"},{"issue":"3","key":"5320_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","volume":"66","author":"G Indolfi","year":"2018","unstructured":"Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N et al (2018) Treatment of chronic hepatitis C virus infection in children: a position paper by the hepatology committee of European society of paediatric Gastroenterology, hepatology and nutrition. J Pediatr Gastroenterol Nutr 66(3):505\u2013515","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"5320_CR18","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","volume":"128","author":"L Castera","year":"2005","unstructured":"Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M et al (2005) Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128(2):343\u2013350","journal-title":"Gastroenterology"},{"key":"5320_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/TCRM.S326099","volume":"20","author":"D Brigham","year":"2024","unstructured":"Brigham D, Narkewicz MR (2024) Profile of Sofosbuvir and velpatasvir combination in the treatment of chronic hepatitis C in children and adolescents: current evidence. Ther Clin Risk Manag 20:1\u20137","journal-title":"Ther Clin Risk Manag"},{"key":"5320_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/s43066-025-00430-2","volume":"15","author":"S Mahmud","year":"2025","unstructured":"Mahmud S, Hossain MB, Haque E, Baidya M, Rashid R, Hasan AR et al (2025) Effectiveness and safety of sofosbuvir\/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children. Egypt Liver J 15:30","journal-title":"Egypt Liver J"},{"key":"5320_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/v13081518","author":"M Pokorska-\u015apiewak","year":"2021","unstructured":"Pokorska-\u015apiewak M, Dobrzeniecka A, Marczy\u0144ska M (2021) One-year outcomes after Ledipasvir\/Sofosbuvir treatment of chronic hepatitis C in teenagers with and without significant liver fibrosis-a case series report. Viruses. https:\/\/doi.org\/10.3390\/v13081518","journal-title":"Viruses"},{"issue":"4","key":"5320_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S2352-4642(25)00028-8","volume":"9","author":"RP Gonzalez-Peralta","year":"2025","unstructured":"Gonzalez-Peralta RP, Wen JW, Hardikar W, Karnsakul WW, Whitworth S, Lin CH et al (2025) Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study. Lancet Child Adolesc Health 9(4):248\u2013254","journal-title":"Lancet Child Adolesc Health"},{"issue":"3","key":"5320_CR23","doi-asserted-by":"publisher","first-page":"266","DOI":"10.5114\/polp.2024.143135","volume":"99","author":"M Pokorska-\u015apiewak","year":"2024","unstructured":"Pokorska-\u015apiewak M, Dobrzeniecka A, Marczy\u0144ska M (2024) Eight-week treatment with sofosbuvir\/velpatasvir may be effective in curing hepatitis c in children. Pediatr Pol 99(3):266\u2013269","journal-title":"Pediatr Pol"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-025-05320-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-025-05320-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:43:46Z","timestamp":1773409426000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-025-05320-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,23]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["5320"],"URL":"https:\/\/doi.org\/10.1007\/s10096-025-05320-4","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,23]]},"assertion":[{"value":"14 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The investigation was performed in accordance with the ethical standards of the 1964 Declaration of Helsinki and its later amendments. Written informed consent was obtained from all the patients and\/or their parents\/guardians before their inclusion in the study. The local ethics committee of the Medical University of Warsaw approved both the PANDAA-PED Study and the POLAC Project (approval numbers KB\/87\/2019, 13 May 2019; KB\/136\/2020, September 14, 2020; No KB\/91\/A2020, 14 October 2020; and KB\/30\/A2021, April 19, 2021; No KB\/73\/A2022, November 7, 2022).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}